Valuation: Actuate Therapeutics, Inc.

Market Cap 14.53M 12.95M 12M 10.91M 20.47M 1.38B 20.8M 144M 56.58M 720M 54.51M 53.37M 2.3B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 14.53M 12.95M 12M 10.91M 20.47M 1.38B 20.8M 144M 56.58M 720M 54.51M 53.37M 2.3B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
84.59%
Yield 2026 *
-
Yield 2027 * -
1 day-0.02%
1 week-6.03%
Current month-22.42%
1 month-33.33%
3 months-56.79%
6 months-76.91%
Current year-90.12%
1 week 0.41
Extreme 0.41
0.71
1 month 0.41
Extreme 0.41
1.02
Current year 0.41
Extreme 0.41
7.05
1 year 0.41
Extreme 0.41
7.9
3 years 0.41
Extreme 0.41
11.99
5 years 0.41
Extreme 0.41
11.99
10 years 0.41
Extreme 0.41
11.99
Manager TitleAgeSince
Corporate Officer/Principal - 2014-12-31
Chief Executive Officer 64 2015-02-28
Director of Finance/CFO 58 2024-01-31
Director TitleAgeSince
Director/Board Member 64 2015-03-31
Chairman 46 2015-03-31
Director/Board Member 66 2021-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 Exercice

Chief Executive Officer

664,633 2.7779%
5/21/26 Free

Director

15,000 0.0633%
5/21/26 Free

Director

15,000 0.0633%
Change 5-day change 1-year change 3-year change Capi.($)
-1.95%-6.03%-91.81% - 14.53M
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+6.83%+10.89%+79.30% 51.2B
+0.30%-0.46%-0.03%+61.89% 51.19B
-0.65%+1.00%+24.89%+41.81% 43.93B
+0.84%+5.83%+16.40%+133.71% 41.96B
+2.81%-5.80%+238.27%+530.00% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+2.21%+27.96%+28.00% 22.5B
Average +0.87%+0.04%+33.42%+111.51% 37.24B
Weighted average by Cap. +0.98%+0.04%+45.58%+112.61%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Projected Income Statement - Annual - Actuate Therapeutics, Inc.
Logo Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Employees
-
Date Price Change Volume
26-10-19 US$0.6049 -0.02% 582,131
26-10-16 US$0.6050 +21.02% 926,163
26-10-15 US$0.4999 +15.13% 472,151
26-10-14 US$0.4342 -6.88% 439,465
26-10-13 US$0.4663 -27.56% 974,397
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6050USD
Average target price
11.68USD
Spread / Average Target
+1,831.13%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Actuate Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ACTU Stock